JPMorgan Chase & Co. Increases Cooper Companies (NASDAQ:COO) Price Target to $78.00

Cooper Companies (NASDAQ:COO) had its price objective lifted by JPMorgan Chase & Co. from $66.00 to $78.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential downside of 4.18% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a report on Friday. Barclays started coverage on shares of Cooper Companies in a research report on Monday, October 13th. They set an “overweight” rating and a $85.00 target price on the stock. Robert W. Baird lifted their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday. Mizuho set a $100.00 price target on Cooper Companies and gave the stock an “outperform” rating in a research note on Friday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Cooper Companies in a research note on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cooper Companies currently has an average rating of “Moderate Buy” and an average price target of $90.31.

Cooper Companies Stock Performance

NASDAQ COO opened at $81.40 on Friday. The stock has a market capitalization of $16.18 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 2.00 and a beta of 1.05. The business’s 50 day moving average is $72.29 and its two-hundred day moving average is $71.67. Cooper Companies has a 12-month low of $61.78 and a 12-month high of $101.53. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 10.01% and a net margin of 9.16%.Cooper Companies’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Research analysts expect that Cooper Companies will post 3.98 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a stock buyback plan on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Cooper Companies

In other news, Director Lawrence Erik Kurzius bought 2,000 shares of Cooper Companies stock in a transaction on Monday, September 29th. The shares were bought at an average cost of $68.39 per share, for a total transaction of $136,780.00. Following the acquisition, the director owned 5,777 shares in the company, valued at approximately $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.98% of the stock is currently owned by insiders.

Institutional Trading of Cooper Companies

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in Cooper Companies by 332.9% in the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after purchasing an additional 4,756,178 shares during the last quarter. Sustainable Growth Advisers LP acquired a new stake in Cooper Companies in the 2nd quarter worth about $240,881,000. JANA Partners Management LP purchased a new stake in Cooper Companies in the 3rd quarter valued at about $166,917,000. Capital World Investors increased its stake in shares of Cooper Companies by 25.7% during the 3rd quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock valued at $723,417,000 after acquiring an additional 2,159,233 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Cooper Companies by 98.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after acquiring an additional 1,683,561 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.